Amgen Inc.
SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND
Last updated:
Abstract:
The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure ##STR00001## useful for the synthesis of compounds that target KRAS G12C mutations, such as ##STR00002##
Status:
Application
Type:
Utility
Filling date:
8 Mar 2022
Issue date:
14 Jul 2022